North America’s medical devices industry saw a rise of 10.11% in deal activity during March 2021

North America’s medical devices industry saw a rise of 10.11% in deal activity during March 2021, when compared with the last 12-month average, led by Hellman & Friedman’s $1bn acquisition of Cardinal Health, according to GlobalData’s deals database.

 

A total of 98 medical devices industry deals worth $4.89bn were announced for the region in March 2021, against the 12-month average of 89 deals.

Of all the deal types, venture financing saw most activity in March 2021 with 64 transactions, representing a 65.3% share for the region.

In second place was M&A with 26 deals, followed by private equity deals with eight transactions, respectively capturing a 26.5% and 8.2% share of the overall deal activity for the month.

In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $2.41bn, while venture financing and private equity deals totalled $1.3bn and $1.18bn, respectively.

North America medical devices industry deals in March 2021: Top deals

The top five medical devices deals accounted for 55.8% of the overall value during March 2021.

The combined value of the top five medical devices deals stood at $2.73bn, against the overall value of $4.89bn recorded for the month.

The top five medical devices industry deals of March 2021 tracked by GlobalData were:

1) Hellman & Friedman’s $1bn private equity deal with Cardinal Health

2) The $695m acquisition deal with Resolution Bioscience by Agilent Technologies

3) Agiliti’s $475m acquisition of Northfield Medical

4) The $320m acquisition of Asuragen by Bio Techne

5) Organon &’s acquisition of Alydia Health for $240m.